SET

Across TCGA pan-cancer cohorts, SET mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SET data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SET mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SET expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where SET mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	1.000	0.268	.003	19	view →
LSCC	DFS	Tertile	II,III,IV	0.889	0.481	.010	11	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	11	view →
LUAD	DFS	Quartile	II,III,IV	0.991	0.625	.016	9	view →
HNSC	DFS	Quartile	All	0.581	0.829	.019	7	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SET–CCRCC (DFS)

Open the CCRCC breakdown →